VJOncology is committed to improving our service to you

ASCO 2020 | Neoadjuvant androgen deprivation therapy in men with high-risk localized prostate cancer

VJOncology is committed to improving our service to you

Rana McKay

Rana R. McKay, MD, of UC San Diego Health, La Jolla, CA, discusses results of a phase II study evaluating abiraterone + prednisone + apalutamide + leuprolide (APAL) or abiraterone + prednisone + leuprolide (APL) in the neoadjuvant setting prior to radical prostatectomy for high risk, localized, prostate cancer patients (NCT02903368). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter